Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Notice of Q3 2020 Trading Update

22nd Jul 2020 09:00

RNS Number : 7478T
UDG Healthcare Public Limited Co.
22 July 2020
 

22 July 2020

 

 

 

UDG Healthcare plc

 

Notice of Q3 2020 Trading Update

 

 

UDG Healthcare plc ("UDG Healthcare" or "Group"), a leading international healthcare services provider, will issue a trading update for the third quarter to 30 June 2020 at 7.00 a.m. (BST) on Wednesday, 5 August 2020.

 

The Company will also host a conference call for investors and analysts at 9.00am (BST) on Wednesday, 5 August 2020 to discuss the statement.

 

Date: Wednesday, 5 August 2020

 

Time: Presentation commencing at 9.00am. Please dial in at 8.45am to ensure a timely start to the briefing.

 

Conference call registration link:

https://secure.emincote.com/client/udghealthcare/udg004/vip_connect

It is suggested participants register in advance to obtain their unique dial-in details.

 

A playback facility will be available for seven days on +44 (0)1212604862. The access code for the replay will be 20200805.

 

For further information, please contact:

 

Keith Byrne

Head of Investor Relations, Strategy & Corporate Communications

UDG Healthcare plc

Tel: +353-1-468-9000

 

Lisa Kavanagh / Ella Morris

Powerscourt

Tel: +44-207-250-1446

Email: [email protected]

About UDG Healthcare plc:

UDG Healthcare plc (LON: UDG) is a FTSE 250 global leader in the healthcare advisory, communications, commercial, clinical and packaging services industries. UDG employs 9,000 people across operations in 29 countries, delivering services in over 50 countries.

Operating across two divisions, Ashfield and Sharp, UDG provides outsourced services which enable over 300 healthcare companies from large pharmaceutical to small biotech to bring their products to market.

Ashfield is a global leader in commercialisation services for the pharmaceutical and healthcare industry, operating across three business areas: Advisory, Communications and Commercial & Clinical. The division focuses on supporting patients to access and adhere to their medications and educating and communicating effectively with healthcare professionals and patients on these products at all stages of the product life cycle. Ashfield provides strategic consulting, advisory services, patient solutions, scientific and creative communications, PR, on-demand advertising services, field and contact centre sales teams, and medical information and event management services.

Sharp is a global leader in contract commercial packaging, clinical, manufacturing and technology services for the pharmaceutical and biotechnology industries, operating from eight state-of-the-art facilities in the US and Europe.

For more information, please go to: www.udghealthcare.com

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TSTRTMRTMTITMMM

Related Shares:

UDG.L
FTSE 100 Latest
Value8,275.66
Change0.00